Clinical Nutrition For Chronic Kidney Diseases Market To Reach $2.37 Billion By 2030

Clinical Nutrition For Chronic Kidney Diseases Market Growth & Trends

The global clinical nutrition for chronic kidney diseases market size is estimated to reach USD 2.37 billion by 2030, growing at a CAGR of 6.03% during the forecast period, according to a new report by Grand View Research, Inc. chronic kidney diseases (CKDs) present a substantial challenge, notably in low- and middle-income countries that lack adequate resources for effective management. Globally, CKD has emerged as a significant cause of death and is one of the rare non-communicable diseases experiencing an increase in mortality rates over the past two decades.

The rising global incidence of CKDs has led to the creation of a diverse array of nutritional supplements designed to address the specific dietary needs of CKD patients. This trend emphasizes the significance of continuous research and innovation in developing efficient and secure supplements that promote kidney health and overall well-being for individuals suffering from CKD.

The increasing awareness among the people and healthcare professionals to treat such deficiencies has resulted in the rising demand for oral clinical nutrition products. Research in natural compounds and nutraceuticals has expanded the scope for market growth. Some prominent examples include nutraceuticals comprising polyunsaturated fatty acids, phytosterols, and phenolic compounds. Moreover, plant-derived compounds such as resveratrol and curcumin have been proven effective in reducing oxidative stress, thus slowing CKD progression and the consequent cardiovascular threats.

Technological advancements in allied industries, such as enteral feeding devices, positively impact market growth. Key players are launching products that can be administered through the enteral route, propelling the market growth. Furthermore, government support in the form of approvals is anticipated to fuel the market growth over the forecast period.

 Request a free sample copy or view report summary: Clinical Nutrition For Chronic Kidney Diseases Market Report

Clinical Nutrition For Chronic Kidney Diseases Market Report Highlights

• Unhealthy lifestyles have led to the increasing burden of health issues such as lack of nutrition, obesity, poor immunity leading to the rise of chronic, neurological and autoimmune diseases.

• Mergers, collaborations, partnerships, and product expansions characterize the market and propel market growth.

• Oral nutrition dominated the product segment with a share of over 50% in 2023; however, parenteral formulas are anticipated to register lucrative growth in the future.

• Adults led the stage segment with a revenue share of 85%. Individuals in the adult age group are increasingly experiencing decreased muscle strength, vitamin and calcium deficiencies, particularly among women over 30 years old, which has led to the segment growth.

• Advancements in telemedicine have enabled the global distribution of clinical nutrition products, allowing manufacturers to broaden their market reach and cater to underserved communities. Thus, online sales are expected to aid market growth greatly over the forecast period.

• Asia Pacific is anticipated to register the fastest CAGR of nearly 7% over the forecast period, owing to the increasing manufacturing facilities in the region and increased per capita healthcare expenditure.

Clinical Nutrition For Chronic Kidney Diseases Market Segmentation

Grand View Research has segmented the global clinical nutrition for chronic kidney diseases market based on product, stage, sales channel, and region:

Clinical Nutrition For Chronic Kidney Diseases Product Outlook (Revenue, USD Million, 2018 - 2030)

• Oral Nutrition

• Parenteral Nutrition

• Enteral Feeding Formulas

Clinical Nutrition For Chronic Kidney Diseases Stage Outlook (Revenue, USD Million, 2018 - 2030)

• Adult

• Pediatric

Clinical Nutrition For Chronic Kidney Diseases Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Online

• Retail

• Institutional Sales

Clinical Nutrition For Chronic Kidney Diseases Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Clinical Nutrition For Chronic Kidney Diseases Market

• Abbott Laboratories

• Pfizer Inc.

• Bayer AG

• Nestle S.A.

• GlaxoSmithKline plc

• Baxter International Inc.

• Otsuka Holdings Co., Ltd.

• Mead Johnson & Company, LLC

• Danone Nutricia, Victus, Inc.